Nuclear imaging of hormonal receptor status in breast cancer: A tool for guiding endocrine treatment and drug development

Current Cancer Drug Targets

Volumn 7, Issue 6, 2007, Pages 510-519

  De Vries, E F J ^a   Rots, M G ^a   Hospers, G A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Breast cancer; Estrogen receptor; Estrogen responsive gene; Gene expression modulation; Medical endocrine treatment; Positron emission tomography; Progesterone receptor; Therapy resistance

Indexed keywords

17ALPHA IODOVINYL 18 METHYL 11 METHYLENE 19 NORTESTOSTERONE; 17ALPHA IODOVINYL 19 NORTESTOSTERONE I 125; 5 AZA 2' DEOXYCYTIDINE; AMINOGLUTETHIMIDE; BENZAMIDE; BENZISOTHIAZOLONE DERIVATIVE; DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR; FLUORINE 18; FLUORO 17BETA ESTRADIOL F 18; FULVESTRANT; GALLIUM 68; GESTAGEN; HISTONE DEACETYLASE INHIBITOR; HORMONE RECEPTOR; MEDROXYPROGESTERONE; PENTETREOTIDE; PROGESTERONE RECEPTOR; SOMATOSTATIN RECEPTOR; TAMOXIFEN; THIAZOLE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CANCER SURGERY; DISEASE COURSE; DRUG BINDING; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; GENE SILENCING; HORMONAL THERAPY; HUMAN; IMAGING; INTERMETHOD COMPARISON; MORBIDITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34548423772     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907781662301     Document Type: Review

References (107)

1. Zidan, J.; Dashkovsky, I.; Stayerman, C.; Basher, W.; Cozacov, C.; Hadary, A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br. J. Cancer 2005, 93, 552-556.
2. Solomayer, E. F.; Becker, S.; Pergola-Becker, G.; Bachmann, R.; Kramer, B.; Vogel, U.; Neubauer, H.; Wallwiener, D.; Huober, J.; Fehm, T. N. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res. Treat. 2006, 98, 179-184.
3. Smith, I. C.; Welch, A. E.; Hutcheon, A. W.; Miller, I. D.; Payne, S.; Chilcott, F.; Waikar, S.; Whitaker, T.; Ah-See, A. K.; Eremin, O.; Heys, S. D.; Gilbert, F. J.; Sharp, P. F. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J. Clin. Oncol. 2000, 18, 1676-1688.
4. Dehdashti, F.; Flanagan, F. L.; Mortimer, J. E.; Katzenellenbogen, J. A.; Welch, M. J.; Siegel, B. A. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur. J. Nucl. Med. 1999, 26, 51-56.
5. Sarfaty, G.; Tallis, M. Probability of a woman with advanced breast cancer responding to adrenalectomy or hypophysectomy. Lancet 1970, 2, 685-687.
6. Nomura, Y.; Tashiro, H.; Osaki, A. Long term survival and the prognostic factors of advanced breast cancer patients treated with adrenooophorectomy. Breast Cancer Res. Treat. 1995, 33, 47-54.
7. Harvey, H. A.; Santen, R. J.; Osterman, J.; Samojlik, E.; White, D. S.; Lipton, A. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 1979, 43, 2207-2214.
8. Smith, I. E.; Ford, H. T.; Gazet, J. C.; Powles, T. J. Premarin in the management of metastatic breast carcinoma in post-menopausal patients. Clin. Oncol. 1979, 5, 159-162.
9. Kennedy, B. J. Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer 1962, 15, 641-648.
10. Muss, H. B.; Case, L. D.; Atkins, J. N.; Bearden, J. D., III; Cooper, M. R.; Cruz, J. M.; Jackson, D. V. Jr.; O'Rourke, M. A.; Pavy, M. D.; Powell, B. L. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J. Clin. Oncol. 1994, 12, 1630-1638.
11. Brufman, G.; Biran, S. Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. Acta Oncol. 1990, 29, 717-720.
12. Peethambaram, P. P.; Ingle, J. N.; Suman, V. J.; Hartmann, L. C.; Loprinzi, C. L. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res. Treat. 1999, 54, 117-122.
13. Dombernowsky, P.; Smith, I.; Falkson, G.; Leonard, R.; Panasci, L.; Bellmunt, J.; Bezwoda, W.; Gardin, G.; Gudgeon, A.; Morgan, M.; Fornasiero, A.; Hoffmann, W.; Michel, J.; Hatschek, T.; Tjabbes, T.; Chaudri, H. A.; Hornberger, U.; Trunet, P. F. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 1998, 16, 453-461.
14. Buzdar, A. U.; Jonat, W.; Howell, A.; Jones, S. E.; Blomqvist, C. P.; Vogel, C. L.; Eiermann, W.; Wolter, J. M.; Steinberg, M.; Webster, A.; Lee, D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83, 1142-1152.
15. Gershanovich, M.; Chaudri, H. A.; Campos, D.; Lurie, H.; Bonaventura, A.; Jeffrey, M.; Buzzi, F.; Bodrogi, I.; Ludwig, H.; Reichardt, P.; O'Higgins, N.; Romieu, G.; Friederich, P.; Lassus, M. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann. Oncol. 1998, 9, 639-645.
16. Song, R. X.; Mor, G.; Naftolin, F.; McPherson, R. A.; Song, J.; Zhang, Z.; Yue, W.; Wang, J.; Santen, R. J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J. Natl. Cancer Inst. 2001, 93, 1714-1723.
17. Song, R. X.; Santen, R. J. Apoptotic action of estrogen. Apoptosis 2003, 8, 55-60.
18. Lonning, P. E.; Taylor, P. D.; Anker, G.; Iddon, J.; Wie, L.; Jorgensen, L. M.; Mella, O.; Howell, A. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res. Treat. 2001, 67, 111-116.
19. Gutierrez, M. C.; Detre, S.; Johnston, S.; Mohsin, S. K.; Shou, J.; Allred, D. C.; Schiff, R.; Osborne, C. K.; Dowsett, M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 2005, 23, 2469-2476.
20. Herynk, M. H.; Fuqua, S. A. Estrogen receptor mutations in human disease. Endocr. Rev. 2004, 25, 869-898.
21. Massarweh, S.; Schiff, R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin. Cancer Res. 2007, 13, 1950-1954.
22. Munzone, E.; Curigliano, G.; Rocca, A.; Bonizzi, G.; Renne, G.; Goldhirsch, A.; Nole, F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res. 2006, 8, R4.
23. Normanno, N.; Di Maio, M.; De Maio, E.; De Luca, A.; de Matteis, A.; Giordano, A.; Perrone, F. On behalf of the NCI-Naples Breast Cancer Group Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 2005, 12, 721-747.
24. Schiff, R.; Massarweh, S.; Shou, J.; Osborne, C. K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 2003, 9, 447S-454S.
25. Jordan, V. C.; Lewis, J. S.; Osipo, C.; Cheng, D. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast 2005, 14, 624-630.
26. Santen, R. J.; Song, R. X.; Zhang, Z.; Yue, W.; Kumar, R. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin. Cancer Res. 2004, 10, 337S-345S.
27. Carter, A. C.; Sedransk, N.; Kelley, R. M.; Ansfield, F. J.; Ravdin, R. G.; Talley, R. W.; Potter, N. R. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 1977, 237, 2079-8.
28. Seimbille, Y.; Benard, F.; Rousseau, J.; Pepin, E.; Aliaga, A.; Tessier, G.; van Lier, J. E. Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16alpha-position of fulvestrant (faslodex; ICI 182, 780). Nucl. Med. Biol. 2004, 31, 691-698.
29. Yang, D. J.; Li, C.; Kuang, L. R.; Price, J. E.; Buzdar, A. U.; Tansey, W.; Cherif, A.; Gretzer, M.; Kim, E. E.; Wallace, S. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci. 1994, 55, 53-67.
30. Van de Wiele, C.; Cocquyt, V.; VandenBroecke, R.; De Vos, F.; Van Belle, S.; Dhaene, K.; Slegers, G.; Dierckx, R. A. Iodine-labeled tamoxifen uptake in primary human breast carcinoma. J. Nucl. Med. 2001, 42, 1818-1820.
31. Inoue, T.; Kim, E. E.; Wallace, S.; Yang, D. J.; Wong, F. C.; Bassa, P.; Cherif, A.; Delpassand, E.; Buzdar, A.; Podoloff, D. A. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother. Radiopharm. 1996, 11, 235-245.
32. Schober, O.; Scheidhauer, K.; Jackisch, C.; Schicha, H.; Smolarz, K.; Bolte, A.; Reiners, C.; Hoffken, K.; Biersack, H. J.; Briele, B.; Breast cancer imaging with radioiodinated oestradiol. Lancet 1990, 335, 1522.
33. Scheidhauer, K.; Muller, S.; Smolarz, K.; Brautigam, P.; Briele, B. [Tumor scintigraphy using 123I-labeled estradiol in breast cancer - receptor scintigraphy]. Nuklearmedizin 1991, 30, 84-99.
34. Kenady, D. E.; Pavlik, E. J.; Nelson, K.; van Nagell, J. R.; Gallion, H.; DePriest, P. D.; Ryo, U. Y.; Baranczuk, R. J. Images of estrogen-receptor- positive breast tumors produced by estradiol labeled with iodine I 123 at 16 alpha. Arch. Surg. 1993, 128, 1373-1381.
35. Rijks, L. J.; Bakker, P. J.; van Tienhoven, G.; Noorduyn, L. A.; Boer, G. J.; Rietbroek, R. C.; Taat, C. W.; Janssen, A. G.; Veenhof, C. H.; van Royen, E. A. Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVE. J. Clin. Oncol. 1997, 15, 2536-2545.
36. 123I]iodovinylestradiol in healthy women and breast cancer patients. J. Nucl. Med. 1999, 40, 1728-1736.
37. Bennink, R. J.; Rijks, L. J.; van Tienhoven, G.; Noorduyn, L. A.; Janssen, A. G.; Sloof, G. W. Estrogen receptor status in primary breast cancer: iodine 123-labeled cis-11beta-methoxy-17alpha-iodovinyl estradiol scintigraphy. Radiology 2001, 220, 774-779.
38. Romer, J.; Steinbach, J.; Kasch, H. Studies on the synthesis of 16 alpha-[F-18]fluoroestradiol. Appl. Radiat. Isot. 1996, 47, 395-399.
39. Romer, J.; Fuchtner, F.; Steinbach, J.; Johanssen, B. Automated production of 16 alpha-[F-18]fluoroestradiol for breast cancer imaging. Nucl. Med. Biol. 1999, 26, 473-479.
40. 18F]fluoro-17β-estradiol. J. Med. Chem. 2005, 48, 6366-6378.
41. Kiesewetter, D. O.; Kilbourn, M. R.; Landvatter, S. W.; Heiman, D. F.; Katzenellenbogen, J. A.; Welch, M. J. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J. Nucl. Med. 1984, 25, 1212-1221.
42. Sasaki, M.; Fukumura, T.; Kuwabara, Y.; Yoshida, T.; Nakagawa, M.; Ichiya, Y.; Masuda, K. Biodistribution and breast tumor uptake of 16 alpha-[F-18]-fluoro-17 beta-estradiol in rat. Ann. Nucl. Med. 2000, 14, 127-130.
43. Seimbille, Y.; Rousseau, J.; Benard, F.; Morin, C.; Ali, H.; Avvakumov, G.; Hammond, G. L.; van Lier, J. E. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 2002, 67, 765-775.
44. Aliaga, A.; Rousseau, J. A.; Ouellette, R.; Cadorette, J.; van Lier, J. E.; Lecomte, R.; Benard, F. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl. Med. Biol. 2004, 31, 761-770.
45. Moresco, R. M.; Casati, R.; Lucignani, G.; Carpinelli, A.; Schmidt, K.; Todde, S.; Colombo, F.; Fazio, F. Systemic and cerebral kinetics of 16 alpha [18F]fluoro-17 beta-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters. J. Cereb. Blood Flow Metab. 1995, 15, 301-311.
46. Katzenellenbogen, J. A.; Mathias, C. J.; VanBrocklin, H. F.; Brodack, J. W.; Welch, M. J. Titration of the in vivo uptake of 16 alpha-[18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development. Nucl. Med. Biol. 1993, 20, 735-745.
47. Mankoff, D. A.; Peterson, L. M.; Tewson, T. J.; Link, J. M.; Gralow, J. R.; Graham, M. M.; Krohn, K. A. [18F]fluoroestradiol radiation dosimetry in human PET studies. J. Nucl. Med. 2001, 42, 679-684.
48. Mintun, M. A.; Welch, M. J.; Siegel, B. A.; Mathias, C. J.; Brodack, J. W.; McGuire, A. H.; Katzenellenbogen, J. A. Breast cancer: PET imaging of estrogen receptors. Radiology 1988, 169, 45-48.
49. Dehdashti, F.; Mortimer, J. E.; Siegel, B. A.; Griffeth, L. K.; Bonasera, T. J.; Fusselman, M. J.; Detert, D. D.; Cutler, P. D.; Katzenellenbogen, J. A.; Welch, M. J. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J. Nucl. Med. 1995, 36, 1766-1774.
50. Mortimer, J. E.; Dehdashti, F.; Siegel, B. A.; Katzenellenbogen, J. A.; Fracasso, P.; Welch, M. J. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin. Cancer Res. 1996, 2, 933-939.
51. Osborne, C. K.; Schiff, R. Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 2005, 23, 1616-1622.
52. Xu, Y.; Berelowitz, M.; Bruno, J. F. Characterization of the promoter region of the human somatostatin receptor subtype 2 gene and localization of sequences required for estrogen-responsiveness. Mol. Cell Endocrinol. 1998, 139, 71-77.
53. Zeng, X.; Yao, Z. Relationship between expression of somatostatin receptors subtype 2 mRNA and estrogen and progesterone receptors in breast cancer. Chin Med. J. (Engl. ) 2003, 116, 1850-1853.
54. Orlando, C.; Raggi, C. C.; Bianchi, S.; Distante, V.; Simi, L.; Vezzosi, V.; Gelmini, S.; Pinzani, P.; Smith, M. C.; Buonamano, A.; Lazzeri, E.; Pazzagli, M.; Cataliotti, L.; Maggi, M.; Serio, M. Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue. Endocr. Relat. Cancer 2004, 11, 323-332.
55. Kumar, U.; Grigorakis, S. I.; Watt, H. L.; Sasi, R.; Snell, L.; Watson, P.; Chaudhari, S. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res. Treat. 2005, 92, 175-186.
56. Djordjijevic, D.; Zhang, J.; Priam, M.; Viollet, C.; Gourdji, D.; Kordon, C.; Epelbaum, J. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures. Endocrinology 1998, 139, 2272-2277.
57. Van Den Bossche, B.; D'haeninck, E.; De Vos, F.; Dierckx, R. A.; Van Belle, S.; Bracke, M.; Van de Wiele, C. Oestrogen-mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1022-1030.
58. Visser-Wisselaar, H. A.; Hofland, L. J.; van Uffelen, C. J.; van Koetsveld, P. M.; Lamberts, S. W. Somatostatin receptor manipulation. Digestion 1996, 57(Suppl 1), 7-10.
59. Xu, Y.; Song, J.; Berelowitz, M.; Bruno, J. F. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 1996, 137, 5634-5640.
60. Virgolini, I.; Traub, T.; Novotny, C.; Leimer, M.; Fuger, B.; Li, S. R.; Patri, P.; Pangerl, T.; Angelberger, P.; Raderer, M.; Burggasser, G.; Andreae, F.; Kurtaran, A.; Dudczak, R. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr. Pharm. Des. 2002, 8, 1781-1807.
61. Kowalski, J.; Henze, M.; Schuhmacher, J.; Macke, H. R.; Hofmann, M.; Haberkorn, U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 2003, 5, 42-48.
62. Meisetschlager, G.; Poethko, T.; Stahl, A.; Wolf, I.; Scheidhauer, K.; Schottelius, M.; Herz, M.; Wester, H. J.; Schwaiger, M. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J. Nucl. Med. 2006, 47, 566-573.
63. Petz, L. N.; Ziegler, Y. S.; Schultz, J. R.; Kim, H.; Kemper, J. K.; Nardulli, A. M. Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J. Steroid Biochem. Mol. Biol. 2004, 88, 113-122.
64. Ali, H.; Rousseau, A. J.; van Lier, J. E. Synthesis of (17 alpha, 20E/Z) iodovinyl testosterone and 19-nortestosterone derivatives as potential radioligands for androgen and progesterone receptors. J. Steroid Biochem. Mol. Biol. 1994, 49, 15-29.
65. Rijks, L. J.; van den Bos, J. C.; van Doremalen, P. A.; Boer, G. J.; de Bruin, K.; Janssen, A. G.; van Royen, E. A. New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 2: In vivo pharmacological characterization. Nucl. Med. Biol. 1998, 25, 791-798.
66. Pomper, M. G.; Katzenellenbogen, J. A.; Welch, M. J.; Brodack, J. W.; Mathias, C. J. 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone: synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography. J. Med. Chem. 1988, 31, 1360-1363.
67. Verhagen, A.; Elsinga, P. H.; de Groot, T. J.; Paans, A. M.; de Goeij, C. J.; Sluyser, M.; Vaalburg, W. A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with positron emission tomography. Cancer Res. 1991, 51, 1930-1933.
68. 18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J. Nucl. Med. 1991, 32, 1532-1537.
69. Verhagen, A.; Studeny, M.; Luurtsema, G.; Visser, G. M.; De Goeij, C. C.; Sluyser, M.; Nieweg, O. E.; Van der Ploeg, E.; Go, K. G.; Vaalburg, W. Metabolism of a [ F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl. Med. Biol. 1994, 21, 941-952.
70. Buckman, B. O.; Bonasera, T. A.; Kirschbaum, K. S.; Welch, M. J.; Katzenellenbogen, J. A. Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J. Med. Chem. 1995, 38, 328-337.
71. Vijaykumar, D.; Mao, W.; Kirschbaum, K. S.; Katzenellenbogen, J. A. An efficient route for the preparation of a 21-fluoro progestin-16 alpha,17 alpha-dioxolane, a high-affinity ligand for PET imaging of the progesterone receptor. J. Org. Chem. 2002, 67, 4904-4910.
72. Zhou, D.; Carlson, K. E.; Katzenellenbogen, J. A.; Welch, M. J. Bromine- and iodine-substituted 16alpha,17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J. Med. Chem. 2006, 49, 4737-4744.
73. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J. Nucl. Med. 1991, 32, 1526-1531.
74. Mortimer, J. E.; Dehdashti, F.; Siegel, B. A.; Trinkaus, K.; Katzenellenbogen, J. A.; Welch, M. J. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J. Clin. Oncol. 2001, 19, 2797-2803.
75. Linden, H. M.; Stekhova, S. A.; Link, J. M.; Gralow, J. R.; Livingston, R. B.; Ellis, G. K.; Petra, P. H.; Peterson, L. M.; Schubert, E. K.; Dunnwald, L. K.; Krohn, K. A.; Mankoff, D. A. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol. 2006, 24, 2793-2799.
76. Van Den Bossche, B.; Van Belle, S.; De Winter, F.; Signore, A.; Van de Wiele, C. Early Prediction of Endocrine Therapy Effect in Advanced Breast Cancer Patients Using 99mTc-Depreotide Scintigraphy. J. Nucl. Med. 2006, 47, 6-13.
77. Lewis-Wambi, J. S.; Jordan, V. C. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Dis. 2005, 24, 93-105.
78. Furukawa, T.; Lohith, T. G.; Takamatsu, S.; Mori, T.; Tanaka, T.; Fujibayashi, Y. Potential of the FES-hERL PET reporter gene system - basic evaluation for gene therapy monitoring. Nucl. Med. Biol. 2006, 33, 145-151.
79. Wang, L. H.; Yang, X. Y.; Zhang, X.; Mihalic, K.; Fan, Y. X.; Xiao, W.; Howard, O. M.; Appella, E.; Maynard, A. T.; Farrar, W. L. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat. Med. 2004, 10, 40-47.
80. Buluwela, L.; Pike, J.; Mazhar, D.; Kamalati, T.; Hart, S. M.; Al-Jehani, R.; Yahaya, H.; Patel, N.; Sarwar, N.; Heathcote, D. A.; Schwickerath, O.; Phoenix, F.; Hill, R.; Aboagye, E.; Shousha, S.; Waxman, J.; Lemoine, N. R.; Zelent, A.; Coombes, R. C.; Ali, S. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF. Gene Ther. 2005, 12, 452-460.
81. Leu, Y. W.; Yan, P. S.; Fan, M.; Jin, V. X.; Liu, J. C.; Curran, E. M.; Welshons, W. V.; Wei, S. H.; Davuluri, R. V.; Plass, C.; Nephew, K. P.; Huang, T. H. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res. 2004, 64, 8184-8192.
82. Liu, W.; Konduri, S. D.; Bansal, S.; Nayak, B. K.; Rajasekaran, S. A.; Karuppayil, S. M.; Rajasekaran, A. K.; Das, G. M. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J. Biol. Chem. 2006, 281, 9837-9840.
83. Gearhart, M. D.; Dickinson, L.; Ehley, J.; Melander, C.; Dervan, P. B.; Wright, P. E.; Gottesfeld, J. M. Inhibition of DNA binding by human estrogen-related receptor 2 and estrogen receptor alpha with minor groove binding polyamides. Biochemistry 2005, 44, 4196-4203.
84. Uil, T. G.; Haisma, H. J.; Rots, M. G. Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Res. 2003, 31, 6064-6078.
85. Kwon, H. S.; Shin, H. C.; Kim, J. S. Suppression of vascular endothelial growth factor expression at the transcriptional and post-transcriptional levels. Nucleic Acids Res. 2005, 33, e74.
86. Segal, D. J. The use of zinc finger peptides to study the role of specific factor binding sites in the chromatin environment. Methods 2002, 26, 76-83.
87. Tan, S.; Guschin, D.; Davalos, A.; Lee, Y. L.; Snowden, A. W.; Jouvenot, Y.; Zhang, H. S.; Howes, K.; McNamara, A. R.; Lai, A.; Ullman, C.; Reynolds, L.; Moore, M.; Isalan, M.; Berg, L. P.; Campos, B.; Qi, H.; Spratt, S. K.; Case, C. C.; Pabo, C. O.; Campisi, J.; Gregory, P. D. Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc. Natl. Acad. Sci. USA 2003, 100, 11997-12002.
88. Gommans, W. M.; Haisma, H. J.; Rots, M. G. Engineering zinc finger protein transcription factors: the therapeutic relevance of switching endogenous gene expression on or off at command. J. Mol. Biol. 2005, 354, 507-519.
89. Gommans, W. M.; McLaughlin, P. M.; Lindhout, B. I.; Segal, D. J.; Wiegman, D. J.; Haisma, H. J.; Van der Zaal, B. J.; Rots, M. G. Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol. Carcinog. 2007, 46, 391-401.
90. Beerli, R. R.; Dreier, B.; Barbas, C. F., III. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA 2000, 97, 1495-1500.
91. Lund, C. V.; Popkov, M.; Magnenat, L.; Barbas, C. F., III. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. Mol. Cell Biol. 2005, 25, 9082-9091.
92. Giacinti, L.; Claudio, P. P.; Lopez, M.; Giordano, A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006, 11, 1-8.
93. Hurtubise, A.; Momparler, R. L. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother. Pharmacol. 2006, 58, 618-625.
94. Keen, J. C.; Yan, L.; Mack, K. M.; Pettit, C.; Smith, D.; Sharma, D.; Davidson, N. E. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res. Treat. 2003, 81, 177-186.
95. Yang, X.; Phillips, D. L.; Ferguson, A. T.; Nelson, W. G.; Herman, J. G.; Davidson, N. E. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001, 61, 7025-7029.
96. Sharma, D.; Saxena, N. K.; Davidson, N. E.; Vertino, P. M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006, 66, 6370-6378.
97. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5, 37-50.
98. Oesterreich, S.; Zhang, P.; Guler, R. L.; Sun, X.; Curran, E. M.; Welshons, W. V.; Osborne, C. K.; Lee, A. V. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res. 2001, 61, 5771-5777.
99. Lazennec, G.; Katzenellenbogen, B. S. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Mol. Cell Endocrinol. 1999, 149, 93-105.
100. Zajchowski, D. A.; Sager, R.; Webster, L. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res. 1993, 53, 5004-5011.
101. Rochefort, H.; Glondu, M.; Sahla, M. E.; Platet, N.; Garcia, M. How to target estrogen receptor-negative breast cancer? Endocr. Relat. Cancer 2003, 10, 261-266.
102. Poola, I.; Speirs, V. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J. Steroid Biochem. Mol. Biol. 2001, 78, 459-469.
103. Poola, I. Molecular assays to profile 10 estrogen receptor beta isoform mRNA copy numbers in ovary, breast, uterus, and bone tissues. Endocrine 2003, 22, 101-112.
104. Rebar, E. J.; Huang, Y.; Hickey, R.; Nath, A. K.; Meoli, D.; Nath, S.; Chen, B.; Xu, L.; Liang, Y.; Jamieson, A. C.; Zhang, L.; Spratt, S. K.; Case, C. C.; Wolffe, A.; Giordano, F. J. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med. 2002, 8, 1427-1432.
105. Dai, Q.; Huang, J.; Klitzman, B.; Dong, C.; Goldschmidt-Clermont, P. J.; March, K. L.; Rokovich, J.; Johnstone, B.; Rebar, E. J.; Spratt, S. K.; Case, C. C.; Kontos, C. D.; Annex, B. H. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 2004, 110, 2467-2475.
106. Price, S. A.; Dent, C.; Duran-Jimenez, B.; Liang, Y.; Zhang, L.; Rebar, E. J.; Case, C. C.; Gregory, P. D.; Martin, T. J.; Spratt, S. K.; Tomlinson, D. R. Gene Transfer of an Engineered Transcription Factor Promoting Expression of VEGF-A Protects Against Experimental Diabetic Neuropathy. Diabetes 2006, 55, 1847-1854.
107. Xie, D.; Li, Y.; Reed, E. A.; Odronic, S. I.; Kontos, C. D.; Annex, B. H. An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J. Vasc. Surg. 2006, 44, 166-175.